← Eichor
Condition: Ovarian Cancer Epithelial Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Ovarian Cancer Epithelial

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Phase 1 · 1 location(s) · Ascentage Pharma Group Inc. · NCT06687070Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
Phase 1 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT04778839Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Pr
Phase 1/Phase 2 · 4 location(s) · Imunon · NCT05739981A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Phase 3 · 106 location(s) · Verastem, Inc. · NCT06072781Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker
Phase N/A · 1 location(s) · University of Aarhus · NCT05763511SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
Phase 2 · 7 location(s) · Institute of Cancer Research, United Kingdom · NCT05990192Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06305299Chemotherapy Supported by Autologous Hematopoietic Stem Cells
NA · 1 location(s) · Chongqing University Cancer Hospital · NCT05401162A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Phase 1 · 15 location(s) · OnCusp Therapeutics, Inc. · NCT06234423Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
Phase 3 · 11 location(s) · Women's Hospital School Of Medicine Zhejiang University · NCT05737303Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemothera
NA · 1 location(s) · Dana-Farber Cancer Institute · NCT04997096Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
NA · 12 location(s) · M.D. Anderson Cancer Center · NCT00539162Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA).
Phase N/A · 1 location(s) · Centro di Riferimento Oncologico - Aviano · NCT06229522Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Tre
Phase 3 · 16 location(s) · Genmab · NCT07225270Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
Phase 1 · 27 location(s) · National Cancer Institute (NCI) · NCT04633239Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1 · 2 location(s) · Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · NCT07156253Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia
Phase N/A · 7 location(s) · Carevive Systems, Inc. · NCT05974150Institut Paoli Calmettes Ovarian Cancer Database
Phase N/A · 1 location(s) · Institut Paoli-Calmettes · NCT02869568Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cance
Phase 2 · 1 location(s) · Bai-Rong Xia · NCT07125391Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients
NA · 1 location(s) · Royal Marsden NHS Foundation Trust · NCT07673861Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer
NA · 1 location(s) · The University of Hong Kong · NCT06292286Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies
Phase N/A · 1 location(s) · University Hospital Tuebingen · NCT05914974Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients
Phase 1 · 1 location(s) · Theolytics Limited · NCT07211659HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT06769425Ultrasensitive SERS Platform With Highly Efficient Enrichment of Analyte for Screening and Diagnosis of Epithelial Ovari
Phase N/A · 1 location(s) · Anhui Provincial Hospital · NCT06640348Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo
Phase 3 · 8 location(s) · Imunon · NCT06915025Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Phase 3 · 53 location(s) · Swiss GO Trial Group · NCT04111978Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
Phase 2 · 1 location(s) · Qilu Hospital of Shandong University · NCT06735326BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Phase 1/Phase 2 · 25 location(s) · BioInvent International AB · NCT04752826
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.